Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Integrin Alpha 4 Market by Type (TE-5232, ATL-1102, Carotegrast, ET-3764, Others), By Application (Acute Ischemic Stroke, Celiac Disease, Epilepsy, Melanoma, Multiple Sclerosis, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Integrin Alpha 4 Market by Type (TE-5232, ATL-1102, Carotegrast, ET-3764, Others), By Application (Acute Ischemic Stroke, Celiac Disease, Epilepsy, Melanoma, Multiple Sclerosis, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 130117 3300 Pharma & Healthcare 377 243 Pages 4.8 (31)
                                          

The global integrin alpha 4 market is expected to grow at a CAGR of XX% during the forecast period. The growth of this market can be attributed to the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. Moreover, the increasing number of patients suffering from these chronic diseases is also driving the growth of this market. The global integrin alpha 4 market by type is segmented into T5232, AT1102, Carotegrast and E3764.The T5232 segment accounted for XX% share in 2018 and it is expected to grow at a CAGR of XX% during the forecast period. The AT1102 segment accounted for xx% share in 2018 and it is expected to grow at a CAGR of xx%. The Carotegrast segment accounted for xx% share in 2018 and it is expected to grow at a CAGR of xx%. The E3764 segment accounted for xx% share in 2018 and it is expected to grow at a CAGR of xx%. The global integrin alpha 4 market by application includes Acute Ischemic Stroke, Celiac Disease, Epilepsy, Melanoma and Multiple Sclerosis. Acute Ischemic Stroke was estimated as one-third (33%) in terms volume sales with an estimated value worth USD XX million in 2018; however its revenue contribution will increase significantly over time due to its high incidence rate among adults aged 45 years or older which will lead towards increased demand for treatment options such as drugs that target integrins alpha4 subunit proteins on endothelial cells lining blood vessels which are responsible for regulating blood flow through them. Multiple Sclerosis was also projected outstandingly large with an estimate size accounting up tp 20%, but there were no data available about how much they contributed financially so far.

Some Of The Growth Factors Of This Market:

  1. The integrin alpha 4 market is driven by the increasing incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases.
  2. The integrin alpha 4 market is also driven by the increasing demand for biologics in the treatment of chronic diseases.
  3. Increasing prevalence of chronic diseases will drive the growth of the integrin alpha 4 market.
  4. Increasing number of clinical trials for new drugs will also drive the growth of this market.

Industry Growth Insights published a new data on “Integrin Alpha 4 Market”. The research report is titled “Integrin Alpha 4 Market research by Types (TE-5232, ATL-1102, Carotegrast, ET-3764, Others), By Applications (Acute Ischemic Stroke, Celiac Disease, Epilepsy, Melanoma, Multiple Sclerosis, Other), By Players/Companies Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, BioMAS Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Viriom Inc”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Integrin Alpha 4 Market Research Report

By Type

TE-5232, ATL-1102, Carotegrast, ET-3764, Others

By Application

Acute Ischemic Stroke, Celiac Disease, Epilepsy, Melanoma, Multiple Sclerosis, Other

By Companies

Amgen Inc, Antisense Therapeutics Ltd, Biogen Inc, BioMAS Ltd, Daiichi Sankyo Co Ltd, EA Pharma Co Ltd, Immunwork Inc, Morphic Therapeutic Inc, Protagonist Therapeutics Inc, Takeda Pharmaceutical Co Ltd, Viriom Inc

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

243

Number of Tables & Figures

171

Customization Available

Yes, the report can be customized as per your need.


Global Integrin Alpha 4 Industry Outlook


Global Integrin Alpha 4 Market Report Segments:

The global Integrin Alpha 4 market is segmented on the basis of:

Types

TE-5232, ATL-1102, Carotegrast, ET-3764, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Acute Ischemic Stroke, Celiac Disease, Epilepsy, Melanoma, Multiple Sclerosis, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Amgen Inc
  2. Antisense Therapeutics Ltd
  3. Biogen Inc
  4. BioMAS Ltd
  5. Daiichi Sankyo Co Ltd
  6. EA Pharma Co Ltd
  7. Immunwork Inc
  8. Morphic Therapeutic Inc
  9. Protagonist Therapeutics Inc
  10. Takeda Pharmaceutical Co Ltd
  11. Viriom Inc

Global Integrin Alpha 4 Market Overview


Highlights of The Integrin Alpha 4 Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. TE-5232
    2. ATL-1102
    3. Carotegrast
    4. ET-3764
    5. Others
  1. By Application:

    1. Acute Ischemic Stroke
    2. Celiac Disease
    3. Epilepsy
    4. Melanoma
    5. Multiple Sclerosis
    6. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Integrin Alpha 4 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Integrin Alpha 4 Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available
                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Integrin Alpha 4 Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Integrin Alpha 4 Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Integrin Alpha 4 Market - Supply Chain
   4.5. Global Integrin Alpha 4 Market Forecast
      4.5.1. Integrin Alpha 4 Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Integrin Alpha 4 Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Integrin Alpha 4 Market Absolute $ Opportunity

5. Global Integrin Alpha 4 Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Integrin Alpha 4 Market Size and Volume Forecast by Type
      5.3.1. TE-5232
      5.3.2. ATL-1102
      5.3.3. Carotegrast
      5.3.4. ET-3764
      5.3.5. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Integrin Alpha 4 Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Integrin Alpha 4 Market Size and Volume Forecast by Application
      6.3.1. Acute Ischemic Stroke
      6.3.2. Celiac Disease
      6.3.3. Epilepsy
      6.3.4. Melanoma
      6.3.5. Multiple Sclerosis
      6.3.6. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Integrin Alpha 4 Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Integrin Alpha 4 Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Integrin Alpha 4 Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Integrin Alpha 4 Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Integrin Alpha 4 Demand Share Forecast, 2019-2029

9. North America Integrin Alpha 4 Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Integrin Alpha 4 Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Integrin Alpha 4 Market Size and Volume Forecast by Application
      9.4.1. Acute Ischemic Stroke
      9.4.2. Celiac Disease
      9.4.3. Epilepsy
      9.4.4. Melanoma
      9.4.5. Multiple Sclerosis
      9.4.6. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Integrin Alpha 4 Market Size and Volume Forecast by Type
      9.7.1. TE-5232
      9.7.2. ATL-1102
      9.7.3. Carotegrast
      9.7.4. ET-3764
      9.7.5. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Integrin Alpha 4 Demand Share Forecast, 2019-2029

10. Latin America Integrin Alpha 4 Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Integrin Alpha 4 Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Integrin Alpha 4 Market Size and Volume Forecast by Application
      10.4.1. Acute Ischemic Stroke
      10.4.2. Celiac Disease
      10.4.3. Epilepsy
      10.4.4. Melanoma
      10.4.5. Multiple Sclerosis
      10.4.6. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Integrin Alpha 4 Market Size and Volume Forecast by Type
      10.7.1. TE-5232
      10.7.2. ATL-1102
      10.7.3. Carotegrast
      10.7.4. ET-3764
      10.7.5. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Integrin Alpha 4 Demand Share Forecast, 2019-2029

11. Europe Integrin Alpha 4 Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Integrin Alpha 4 Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Integrin Alpha 4 Market Size and Volume Forecast by Application
      11.4.1. Acute Ischemic Stroke
      11.4.2. Celiac Disease
      11.4.3. Epilepsy
      11.4.4. Melanoma
      11.4.5. Multiple Sclerosis
      11.4.6. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Integrin Alpha 4 Market Size and Volume Forecast by Type
      11.7.1. TE-5232
      11.7.2. ATL-1102
      11.7.3. Carotegrast
      11.7.4. ET-3764
      11.7.5. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Integrin Alpha 4 Demand Share, 2019-2029

12. Asia Pacific Integrin Alpha 4 Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Integrin Alpha 4 Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Integrin Alpha 4 Market Size and Volume Forecast by Application
      12.4.1. Acute Ischemic Stroke
      12.4.2. Celiac Disease
      12.4.3. Epilepsy
      12.4.4. Melanoma
      12.4.5. Multiple Sclerosis
      12.4.6. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Integrin Alpha 4 Market Size and Volume Forecast by Type
      12.7.1. TE-5232
      12.7.2. ATL-1102
      12.7.3. Carotegrast
      12.7.4. ET-3764
      12.7.5. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Integrin Alpha 4 Demand Share, 2019-2029

13. Middle East & Africa Integrin Alpha 4 Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Integrin Alpha 4 Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Integrin Alpha 4 Market Size and Volume Forecast by Application
      13.4.1. Acute Ischemic Stroke
      13.4.2. Celiac Disease
      13.4.3. Epilepsy
      13.4.4. Melanoma
      13.4.5. Multiple Sclerosis
      13.4.6. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Integrin Alpha 4 Market Size and Volume Forecast by Type
      13.7.1. TE-5232
      13.7.2. ATL-1102
      13.7.3. Carotegrast
      13.7.4. ET-3764
      13.7.5. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Integrin Alpha 4 Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Integrin Alpha 4 Market: Market Share Analysis
   14.2. Integrin Alpha 4 Distributors and Customers
   14.3. Integrin Alpha 4 Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Amgen Inc
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Antisense Therapeutics Ltd
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Biogen Inc
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. BioMAS Ltd
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Daiichi Sankyo Co Ltd
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. EA Pharma Co Ltd
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Immunwork Inc
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Morphic Therapeutic Inc
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Protagonist Therapeutics Inc
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Takeda Pharmaceutical Co Ltd
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Viriom Inc
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us